Skip to main content
. 2015 Oct;10(19):2973–2988. doi: 10.2217/nnm.15.138

Figure 6. . Iron accumulates in GD2+ xenografts after intravenous anti-GD2-Bionized NanoFerrite administration.

Figure 6. 

(A) Spectrophotometry of iron content in GD2+ tumors (CHLA-20) in mice that received no injections, or received an intravenous injection of nontargeted nanoparticles (BNF), or of anti-GD2-BNF (aGD2-BNF) nanoparticles 24 h earlier. Average ± standard error, n = 6, 4 and 6, respectively; *p ≤ 0.02. (B) Spectrophotometry of iron content in tumors 24 h after intravenous injection of anti-GD2-BNF in mice bearing flank xenografts of both GD2– tumors (PC3) and GD2+ tumors (CHLA-20; *p = 0.03; n = 4). (C) Histochemistry of nonheme iron in GD2+ xenografts (upper panels) and GD2– xenografts (lower panels) 24 h after injection of BNF or anti-GD2-BNF. (D & E) Spectrophotometry of iron content (averages ± standard error, n as in legend 6A) in brain (Br), skeletal muscle (Mu), skin (Sk), endocardium (He), kidney (Ki), lung (Lu), liver (Li), spleen (Sp) at background levels and 24 h after injection of BNF or anti-GD2-BNF.

BNF: Bionized NanoFerrite.